Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Imaging Technology

MAY 10, 2024

milla1cf Fri, 05/10/2024 - 08:08 May 10, 2024 — Mariana Oncology , a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer , today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.

Radiopharmaceuticals 70

Radiopharmaceuticals Clinic IT 70

Health Imaging

JUNE 15, 2023

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

Radiopharmaceuticals 103

Radiopharmaceuticals Imaging 103

Open Medscience

DECEMBER 28, 2023

Lead radiopharmaceuticals herald a transformative era in cancer treatment with promising, targeted therapeutic approaches. The post Transforming Cancer Treatment: The Promising Future of Lead Radiopharmaceuticals appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical 59

Open Medscience

JANUARY 12, 2024

Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Imaging Nuclear Medicine Medical 52

Open Medscience

JANUARY 24, 2024

The post The Breakthrough Role of Thorium-227 in Theranostic Radiopharmaceuticals appeared first on Open Medscience. Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.

Radiopharmaceuticals 64

Radiopharmaceuticals Nuclear Medicine 64

Open Medscience

NOVEMBER 16, 2023

In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare. The post Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Healthcare Healthcare Disease 59

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

MARCH 22, 2024

The post Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals appeared first on Open Medscience. Nuclear medicine and the future of precise, personalised care in diagnosing and treating diseases.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiology Disease 52

Open Medscience

NOVEMBER 12, 2023

The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience. Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Imaging Technology

OCTOBER 17, 2023

a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, is pleased to announce that the first subject has been dosed in its Phase 1 study of 68Ga-R8760. milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc.,

Radiopharmaceuticals 114

Radiopharmaceuticals Clinic Disease Diagnose 114

AuntMinnie

MAY 8, 2024

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer.

Radiopharmaceuticals 75

Radiopharmaceuticals Nuclear Medicine Radiation Hospital 75

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 98

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 98

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 101

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 101

Imaging Technology

JANUARY 5, 2024

This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Radiopharmaceuticals 84

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 84

AuntMinnie

JUNE 22, 2023

Read more on AuntMinnie.com Related Reading: RLS appoints new director of regulatory affairs SpectronRx, RLS ink radiopharmaceutical supply deal RLS lands radiopharmaceutical supplier deal from Premier Sofie to launch FAPI-PET phase II trial First patient imaged in Sofie's FAPI-PET trial

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging 52

AuntMinnie

SEPTEMBER 13, 2023

Senate MITA hails radiopharmaceutical legislation Read more on AuntMinnie.com Related Reading: ACR urges full coverage for amyloid PET scans CMS proposal covers PET scans for Alzheimer’s disease MITA praises FDA for Leqembi approval FIND Act reintroduced in U.S.

Radiopharmaceuticals 52

Radiopharmaceuticals PET Scan Disease Medical Imaging 52

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 93

Radiopharmaceuticals Imaging Pharmaceutical Disease 93

Imaging Technology

JULY 11, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 73

Radiopharmaceuticals Imaging Pharmaceutical Disease 73

AuntMinnie

JUNE 8, 2023

Radiopharmaceutical manufacturer SpectronRx and nuclear medicine drug distributo.

Radiopharmaceuticals 52

Radiopharmaceuticals Nuclear Medicine Clinic 52

Diagnostic Imaging

JUNE 28, 2023

discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Radiopharmaceuticals 60

Radiopharmaceuticals Nuclear Medicine Imaging 60

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 92

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 92

Radiology Business

JUNE 28, 2024

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

Radiopharmaceuticals 61

Radiopharmaceuticals Diagnostic 61

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Open Medscience

JULY 28, 2019

Radiopharmaceuticals are used in nuclear medicine for the application of medical imaging and therapy. The post Radiopharmaceuticals used in nuclear medicine appeared first on Open Medscience.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Medical Imaging Medical 52

Health Imaging

JANUARY 8, 2024

The new facility is run by Novartis and is being called the “most advanced of its kind."

Radiopharmaceuticals 97

Radiopharmaceuticals IT 97

Radiology Business

MAY 3, 2024

The Swiss drugmaker said the deal will bolster its research infrastructure and clinical supply capabilities, with an eye toward improving oncologic care.

Radiopharmaceuticals 85

Radiopharmaceuticals Clinic IT 85

Radiology Business

MAY 21, 2024

The Indianapolis-based drugmaker can hit the hefty total by reaching certain clinical, regulatory and commercial milestones.

Radiopharmaceuticals 84

Radiopharmaceuticals Clinic 84

AuntMinnie

FEBRUARY 1, 2024

ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, recently received a wholesale license issued by the New Jersey Department of Health to operate as a virtual manufacturer. Since then, it has been preparing for potential market registration of its targeted radiopharmaceutical pipeline product candidates.

Radiopharmaceuticals 96

Radiopharmaceuticals IT 96

Open Medscience

JUNE 22, 2024

Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging Diagnostic Imaging 52

Radiology Business

OCTOBER 18, 2023

Nucleus RadioPharma will use the money to establish manufacturing facilities—with one located in Rochester, Minnesota, near Mayo—and build new technology for distribution.

Radiopharmaceuticals 102

Radiopharmaceuticals Clinic Healthcare Healthcare 102

Radiology Business

SEPTEMBER 11, 2023

The company has developed a portfolio of nuclear medicine solutions including "lead candidate" MC-339, used for treating small cell lung cancer.

Nuclear Medicine 90

Nuclear Medicine Radiopharmaceuticals 90

Health Imaging

APRIL 5, 2024

The supply agreement with Eckert & Ziegler will ensure radiopharmaceuticals are available for PET imaging and cancer treatment plans.

Radiopharmaceuticals 100

Radiopharmaceuticals IT Imaging 100

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 124

Radiopharmaceuticals 124

Radiology Business

JULY 14, 2023

The agency issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday.

Radiopharmaceuticals 82

Radiopharmaceuticals Diagnostic Hospital IT 82

AuntMinnie

MAY 1, 2024

Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).

Radiopharmaceuticals 96

Radiopharmaceuticals Pharmaceutical Radiology 96